Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Weir, RE; Black, GF; Dockrell, HM; Floyd, S; Fine, PE; Chaguluka, SD; Stenson, S; King, E; Nazareth, B; Warndorff, DK; Ngwira, B; Crampin, AC; Mwaungulu, L; Sichali, L; Jarman, E; Donovan, L; Blackwell, JM (2004)
Publisher: American Society for Microbiology
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: parasitic diseases
To investigate the role of innate immunity in variable efficacy of Mycobacterium bovis BCG vaccination in Malawi and the United Kingdom, we examined 24-h tumor necrosis factor alpha, interleukin-1beta (IL-1beta), and IL-10 responses to mycobacterial purified protein derivatives (PPDs). The rank order in stimulatory potency for different PPDs was the same for all three cytokines. Before vaccination Malawians made higher pro- and anti-inflammatory responses than did United Kingdom subjects. Fewer than 5% of United Kingdom subjects made IL-10 in response to any PPD, compared to 19 to 57% responders among Malawians. Priming for regulatory IL-10 may contribute to the smaller increase in gamma interferon responses in Malawians compared to United Kingdom subjects following BCG vaccination.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680.
    • 2. Bendelac, A., and D. T. Fearon. 1997. Innate pathways that control acquired immunity. Curr. Opin. Immunol. 9:1-3.
    • 3. Black, G. F., H. M. Dockrell, A. C. Crampin, S. Floyd, R. E. Weir, L. Bliss, L. Sichali, L. Mwaungulu, H. Kanyongoloka, B. Ngwira, D. K. Warndorff, and P. E. Fine. 2001. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J. Infect. Dis. 184:322-329.
    • 4. Black, G. F., P. E. M. Fine, D. K. Warndorff, S. Floyd, R. E. Weir, J. M. Blackwell, L. Bliss, L. Sichali, L. Mwaungulu, S. Chaguluka, E. Jarman, B. Ngwira, and H. M. Dockrell. 2001. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, nonBCG-vaccinated young adults in northern Malawi. Int. J. Tuberc. Lung Dis. 5:664-672.
    • 5. Black, G. F., R. E. Weir, S. Floyd, L. Bliss, D. K. Warndorff, A. C. Crampin, B. Ngwira, L. Sichali, B. Nazareth, J. M. Blackwell, K. Branson, S. D. Chaguluka, L. Donovan, E. Jarman, E. King, P. E. Fine, and H. M. Dockrell. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359:1393-1401.
    • 6. Edwards, L. B., and C. E. Palmer. 1958. Epidemiologic studies of tuberculin sensitivity. 1. Preliminary results with purified protein derivatives prepared from atypical acid-fast organisms. Am. J. Hyg. 68:213-231.
    • 7. Fearon, D. T. 2000. Innate immunity-beginning to fulfill its promise? Nat. Immunol. 1:102-103.
    • 8. Fearon, D. T. 1997. Seeking wisdom in innate immunity. Nature 388:323- 324.
    • 9. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50-53.
    • 10. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
    • 11. Foey, A. D., S. L. Parry, L. M. Williams, M. Feldmann, B. M. Foxwell, and F. M. Brennan. 1998. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J. Immunol. 160:920-928.
    • 12. Kaur, D., T. L. Lowary, V. D. Vissa, D. C. Crick, and P. J. Brennan. 2002. Characterization of the epitope of anti-lipoarabinomannan antibodies as the terminal hexaarabinofuranosyl motif of mycobacterial arabinans. Microbiology 148:3049-3057.
    • 13. Khoo, K. H., A. Dell, H. R. Morris, P. J. Brennan, and D. Chatterjee. 1995. Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium. J. Biol. Chem. 270: 12380-12389.
    • 14. Khoo, K. H., J. B. Tang, and D. Chatterjee. 2001. Variation in mannosecapped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex. J. Biol. Chem. 276:3863-3871.
    • 15. Magnusson, M., and M. W. Bentzon. 1958. Preparation of purified tuberculin RT23. Bull. W. H. O. 19:829-843.
    • 16. Means, T. K., E. Lien, A. Yoshimura, S. Wang, D. T. Golenbock, and M. J. Fenton. 1999. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163:6748- 6755.
    • 17. Means, T. K., S. Wang, E. Lien, A. Yoshimura, D. T. Golenbock, and M. J. Fenton. 1999. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 163:3920-3927.
    • 18. Medzhitov, R., and C. A. Janeway, Jr. 1997. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9:4-9.
    • 19. Medzhitov, R., and C. A. Janeway, Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295-298.
    • 20. Stanford, J. L., G. A. Rook, N. Samuel, F. Madlener, A. A. Khamenei, T. Nemati, F. Modabber, and R. J. Rees. 1980. Preliminary immunological studies in search of correlates of protective immunity carried out on some Iranian leprosy patients and their families. Lepr. Rev. 51:303-314.
    • 21. Stenger, S., and R. L. Modlin. 2002. Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. Curr. Opin. Immunol. 14:452-457.
    • 22. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-376.
    • 23. Weir, R. E., P. E. M. Fine, B. Nazareth, S. Floyd, G. F. Black, E. King, C. Stanley, L. Bliss, K. Branson, and H. M. Dockrell. 2003. Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria. Clin. Exp. Immunol. 134:285-294.
    • 24. World Health Organization. 1955. International standard for purified protein derivative of avian tuberculin. WHO Tech. Rep. Ser. 96:11.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article